Страница 1+ · 50 сайта
| NCT00002763 | High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma | UNKNOWN | PHASE3 | European Organisation for Research and Treatment of Cancer - EORTC | Melanoma (Skin) | Alexander's University Hospital | Sofia | София - Град |
| NCT00002763 | High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma | UNKNOWN | PHASE3 | European Organisation for Research and Treatment of Cancer - EORTC | Melanoma (Skin) | National Centre of Oncology | Sofia | София - Град |
| NCT00006249 | Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma | UNKNOWN | PHASE3 | European Organisation for Research and Treatment of Cancer - EORTC | Melanoma (Skin) | National Centre of Oncology | Sofia | София - Град |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | COMPLETED | PHASE3 | Sanofi | Breast Neoplasms | Sanofi-Aventis Administrative Office | Vazrjdane Region | София - Град |
| NCT00022672 | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer | COMPLETED | PHASE3 | Hoffmann-La Roche | Breast Cancer | — | Plovdiv | Пловдив |
| NCT00022672 | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer | COMPLETED | PHASE3 | Hoffmann-La Roche | Breast Cancer | — | Sofia | София - Град |
| NCT00022672 | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer | COMPLETED | PHASE3 | Hoffmann-La Roche | Breast Cancer | — | Stara Zagora | Стара Загора |
| NCT00029822 | Clinical Trial in Males With BPH (Enlarged Prostate) | COMPLETED | PHASE3 | Sanofi | Urinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy | Sanofi-aventis Administrative Office | Sofia | София - Град |
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | COMPLETED | PHASE2 | Alexion Pharmaceuticals, Inc. | Hepatitis B, Chronic | Clinical Trial Site | Sofia | София - Град |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 | Pfizer | Breast Neoplasms | Pfizer Investigational Site | Plovdiv | Пловдив |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 | Pfizer | Breast Neoplasms | Pfizer Investigational Site | Sofia | София - Град |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 | Pfizer | Breast Neoplasms | Pfizer Investigational Site | Sofia | София - Град |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 | Pfizer | Breast Neoplasms | Pfizer Investigational Site | Sofia | София - Град |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 | Pfizer | Breast Neoplasms | Pfizer Investigational Site | Stara Zagora | Стара Загора |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | COMPLETED | PHASE3 | GlaxoSmithKline | Small Cell Lung Cancer | GSK Clinical Trials Call Center | Burgas | Бургас |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | COMPLETED | PHASE3 | GlaxoSmithKline | Small Cell Lung Cancer | GSK Clinical Trials Call Center | Plovdiv | Пловдив |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | COMPLETED | PHASE3 | GlaxoSmithKline | Small Cell Lung Cancer | GSK Clinical Trials Call Center | Sofia | София - Град |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | COMPLETED | PHASE3 | GlaxoSmithKline | Small Cell Lung Cancer | GSK Clinical Trials Call Center | Sofia | София - Град |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | COMPLETED | PHASE3 | GlaxoSmithKline | Small Cell Lung Cancer | GSK Clinical Trials Call Center | Varna | Варна |
| NCT00046228 | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) | COMPLETED | PHASE3 | Centocor, Inc. | Myocardial Infarction | — | Dimitrovgrad | Хасково |
| NCT00046228 | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) | COMPLETED | PHASE3 | Centocor, Inc. | Myocardial Infarction | — | Haskovo | Хасково |
| NCT00046228 | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) | COMPLETED | PHASE3 | Centocor, Inc. | Myocardial Infarction | — | Plovdiv | Пловдив |
| NCT00046228 | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) | COMPLETED | PHASE3 | Centocor, Inc. | Myocardial Infarction | — | Sofia | София - Град |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | COMPLETED | PHASE3 | GlaxoSmithKline | Neoplasms, Prostate | GSK Investigational Site | Sofia | София - Град |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | COMPLETED | PHASE3 | GlaxoSmithKline | Neoplasms, Prostate | GSK Investigational Site | Sofia | София - Град |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | COMPLETED | PHASE3 | GlaxoSmithKline | Neoplasms, Prostate | GSK Investigational Site | Sofia | София - Град |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | COMPLETED | PHASE3 | GlaxoSmithKline | Neoplasms, Prostate | GSK Investigational Site | Sofia | София - Град |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk | COMPLETED | PHASE3 | GlaxoSmithKline | Neoplasms, Prostate | GSK Investigational Site | Varna | Варна |
| NCT00057304 | Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Pleven | Плевен |
| NCT00057304 | Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Plovdiv | Пловдив |
| NCT00057304 | Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Sofia | София - Град |
| NCT00057304 | Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Sofia | София - Град |
| NCT00057304 | Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Sofia | София - Град |
| NCT00057317 | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Pleven | Плевен |
| NCT00057317 | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Plovdiv | Пловдив |
| NCT00057317 | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Sofia | София - Град |
| NCT00057317 | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | Hoffmann-La Roche | Diabetes | — | Sofia | София - Град |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | COMPLETED | PHASE3 | Celgene Corporation | Multiple Myeloma | UMHAT Alexandrovska | Alexandrovska | — |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | COMPLETED | PHASE3 | Celgene Corporation | Multiple Myeloma | National Center of Haematology and Transfusiology | Sofia | София - Град |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | COMPLETED | PHASE3 | Celgene Corporation | Multiple Myeloma | Military Medical Academy | Sofia | София - Град |
| NCT00061022 | Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke | COMPLETED | PHASE3 | AstraZeneca | Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient | Research Site | Pleven | Плевен |
| NCT00061022 | Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke | COMPLETED | PHASE3 | AstraZeneca | Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient | Research Site | Plovdiv | Пловдив |
| NCT00061022 | Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke | COMPLETED | PHASE3 | AstraZeneca | Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient | Research Site | Rousse | Русе |
| NCT00061022 | Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke | COMPLETED | PHASE3 | AstraZeneca | Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient | Research Site | Sofia | София - Град |
| NCT00061022 | Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke | COMPLETED | PHASE3 | AstraZeneca | Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient | Research Site | Varna | Варна |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | COMPLETED | PHASE3 | Celgene | Myelodysplastic Syndromes | First Clinical Base - Clinic of Hematology, MHAT - Pleven | Pleven | Плевен |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | COMPLETED | PHASE3 | Celgene | Myelodysplastic Syndromes | MHAT "St George" Clinic of Hematology, Plovdiv | Plovdiv | Пловдив |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | COMPLETED | PHASE3 | Celgene | Myelodysplastic Syndromes | III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU) | Plovdiv | Пловдив |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | COMPLETED | PHASE3 | Celgene | Myelodysplastic Syndromes | National Centre of Hematology and Transfusiology, Sofia | Sofia | София - Град |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | COMPLETED | PHASE3 | Celgene | Myelodysplastic Syndromes | Multiprofile Hospital for Active Treatment (MHAT), "St. Marina" Clinic of Hematology | Varna | Варна |
NCT00002763
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
UNKNOWNPHASE3Sofia · София - Град
Melanoma (Skin)
Спонсор: European Organisation for Research and Treatment of Cancer - EORTC
Alexander's University Hospital
NCT00002763
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
UNKNOWNPHASE3Sofia · София - Град
Melanoma (Skin)
Спонсор: European Organisation for Research and Treatment of Cancer - EORTC
National Centre of Oncology
NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
UNKNOWNPHASE3Sofia · София - Град
Melanoma (Skin)
Спонсор: European Organisation for Research and Treatment of Cancer - EORTC
National Centre of Oncology
NCT00021255
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
COMPLETEDPHASE3Vazrjdane Region · София - Град
Breast Neoplasms
Спонсор: Sanofi
Sanofi-Aventis Administrative Office
NCT00022672
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
COMPLETEDPHASE3Plovdiv · Пловдив
Breast Cancer
Спонсор: Hoffmann-La Roche
NCT00022672
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
COMPLETEDPHASE3Sofia · София - Град
Breast Cancer
Спонсор: Hoffmann-La Roche
NCT00022672
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
COMPLETEDPHASE3Stara Zagora · Стара Загора
Breast Cancer
Спонсор: Hoffmann-La Roche
NCT00029822
Clinical Trial in Males With BPH (Enlarged Prostate)
COMPLETEDPHASE3Sofia · София - Град
Urinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy
Спонсор: Sanofi
Sanofi-aventis Administrative Office
NCT00034359
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
COMPLETEDPHASE2Sofia · София - Град
Hepatitis B, Chronic
Спонсор: Alexion Pharmaceuticals, Inc.
Clinical Trial Site
NCT00038467
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
COMPLETEDPHASE3Plovdiv · Пловдив
Breast Neoplasms
Спонсор: Pfizer
Pfizer Investigational Site
NCT00038467
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
COMPLETEDPHASE3Sofia · София - Град
Breast Neoplasms
Спонсор: Pfizer
Pfizer Investigational Site
NCT00038467
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
COMPLETEDPHASE3Sofia · София - Град
Breast Neoplasms
Спонсор: Pfizer
Pfizer Investigational Site
NCT00038467
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
COMPLETEDPHASE3Sofia · София - Град
Breast Neoplasms
Спонсор: Pfizer
Pfizer Investigational Site
NCT00038467
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
COMPLETEDPHASE3Stara Zagora · Стара Загора
Breast Neoplasms
Спонсор: Pfizer
Pfizer Investigational Site
NCT00043927
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
COMPLETEDPHASE3Burgas · Бургас
Small Cell Lung Cancer
Спонсор: GlaxoSmithKline
GSK Clinical Trials Call Center
NCT00043927
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
COMPLETEDPHASE3Plovdiv · Пловдив
Small Cell Lung Cancer
Спонсор: GlaxoSmithKline
GSK Clinical Trials Call Center
NCT00043927
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
COMPLETEDPHASE3Sofia · София - Град
Small Cell Lung Cancer
Спонсор: GlaxoSmithKline
GSK Clinical Trials Call Center
NCT00043927
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
COMPLETEDPHASE3Sofia · София - Град
Small Cell Lung Cancer
Спонсор: GlaxoSmithKline
GSK Clinical Trials Call Center
NCT00043927
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
COMPLETEDPHASE3Varna · Варна
Small Cell Lung Cancer
Спонсор: GlaxoSmithKline
GSK Clinical Trials Call Center
NCT00046228
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
COMPLETEDPHASE3Dimitrovgrad · Хасково
Myocardial Infarction
Спонсор: Centocor, Inc.
NCT00046228
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
COMPLETEDPHASE3Haskovo · Хасково
Myocardial Infarction
Спонсор: Centocor, Inc.
NCT00046228
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
COMPLETEDPHASE3Plovdiv · Пловдив
Myocardial Infarction
Спонсор: Centocor, Inc.
NCT00046228
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
COMPLETEDPHASE3Sofia · София - Град
Myocardial Infarction
Спонсор: Centocor, Inc.
NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETEDPHASE3Sofia · София - Град
Neoplasms, Prostate
Спонсор: GlaxoSmithKline
GSK Investigational Site
NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETEDPHASE3Sofia · София - Град
Neoplasms, Prostate
Спонсор: GlaxoSmithKline
GSK Investigational Site
NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETEDPHASE3Sofia · София - Град
Neoplasms, Prostate
Спонсор: GlaxoSmithKline
GSK Investigational Site
NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETEDPHASE3Sofia · София - Град
Neoplasms, Prostate
Спонсор: GlaxoSmithKline
GSK Investigational Site
NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETEDPHASE3Varna · Варна
Neoplasms, Prostate
Спонсор: GlaxoSmithKline
GSK Investigational Site
NCT00057304
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Pleven · Плевен
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057304
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Plovdiv · Пловдив
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057304
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Sofia · София - Град
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057304
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Sofia · София - Град
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057304
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Sofia · София - Град
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Pleven · Плевен
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Plovdiv · Пловдив
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Sofia · София - Град
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
COMPLETEDPHASE2Sofia · София - Град
Diabetes
Спонсор: Hoffmann-La Roche
NCT00057564
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
COMPLETEDPHASE3Alexandrovska
Multiple Myeloma
Спонсор: Celgene Corporation
UMHAT Alexandrovska
NCT00057564
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
COMPLETEDPHASE3Sofia · София - Град
Multiple Myeloma
Спонсор: Celgene Corporation
National Center of Haematology and Transfusiology
NCT00057564
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
COMPLETEDPHASE3Sofia · София - Град
Multiple Myeloma
Спонсор: Celgene Corporation
Military Medical Academy
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
COMPLETEDPHASE3Pleven · Плевен
Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient
Спонсор: AstraZeneca
Research Site
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
COMPLETEDPHASE3Plovdiv · Пловдив
Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient
Спонсор: AstraZeneca
Research Site
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
COMPLETEDPHASE3Rousse · Русе
Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient
Спонсор: AstraZeneca
Research Site
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
COMPLETEDPHASE3Sofia · София - Град
Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient
Спонсор: AstraZeneca
Research Site
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
COMPLETEDPHASE3Varna · Варна
Cerebral Stroke; Stroke, Acute; Cerebrovascular Stroke; Ischemic Attack, Transient
Спонсор: AstraZeneca
Research Site
NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
COMPLETEDPHASE3Pleven · Плевен
Myelodysplastic Syndromes
Спонсор: Celgene
First Clinical Base - Clinic of Hematology, MHAT - Pleven
NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
COMPLETEDPHASE3Plovdiv · Пловдив
Myelodysplastic Syndromes
Спонсор: Celgene
MHAT "St George" Clinic of Hematology, Plovdiv
NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
COMPLETEDPHASE3Plovdiv · Пловдив
Myelodysplastic Syndromes
Спонсор: Celgene
III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU)
NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
COMPLETEDPHASE3Sofia · София - Град
Myelodysplastic Syndromes
Спонсор: Celgene
National Centre of Hematology and Transfusiology, Sofia
NCT00071799
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
COMPLETEDPHASE3Varna · Варна
Myelodysplastic Syndromes
Спонсор: Celgene
Multiprofile Hospital for Active Treatment (MHAT), "St. Marina" Clinic of Hematology
Страница 1+